Company

Product

Description

Indication

Status

Date


Alterity Therapeutics Ltd., of Melbourne, Australia

PBT-434

Small-molecule inhibitor of alpha-synuclein aggregation

Synucleino-pathies such as Parkinson's disease and multiple system atrophy

Interim data from phase I trial in healthy volunteers showed drug was well-tolerated in 3 multiple-dose cohorts; PBT-434 crosses the blood-brain barrier in humans and achieved concentrations in the brain exceeding those associated with efficacy in animal models of the disease

5/6/19


Notes

The date indicated refers to the BioWorld table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

 

No Comments